retatrutide patent expiration Will the FDA approve retatrutide? Odds & Predictions Off-patent semaglutide in 2026: the
Description
Common side effects include nausea, constipation, or mild dizziness
Peaka GLP-1 offers no comparable timeline because no clinical data exists to establish one
The FDA-approved, branded versions of GLP-1 products were so popular that the brand manufacturers were not able to keep up with demand, prompting the FDA to declare a shortage for each of the semaglutide and tirzepatide products over the course of 2022
And like I said, if you stop them, there is weight regain
